Earnest Partners LLC decreased its holdings in Humana Inc (NYSE:HUM) by 4.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 126,469 shares of the insurance provider’s stock after selling 5,963 shares during the quarter. Earnest Partners LLC owned approximately 0.09% of Humana worth $31,373,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of HUM. Fieldpoint Private Securities LLC bought a new stake in Humana during the third quarter valued at $115,000. American Beacon Advisors Inc. bought a new stake in Humana during the fourth quarter valued at $122,000. ClariVest Asset Management LLC bought a new stake in Humana during the third quarter valued at $144,000. YorkBridge Wealth Partners LLC boosted its position in Humana by 99.0% during the fourth quarter. YorkBridge Wealth Partners LLC now owns 597 shares of the insurance provider’s stock valued at $159,000 after acquiring an additional 297 shares during the last quarter. Finally, Daiwa SB Investments Ltd. boosted its position in Humana by 44.9% during the fourth quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock valued at $176,000 after acquiring an additional 220 shares during the last quarter. 97.85% of the stock is currently owned by institutional investors.
Humana Inc (NYSE:HUM) opened at $269.98 on Wednesday. Humana Inc has a fifty-two week low of $203.48 and a fifty-two week high of $293.35. The firm has a market cap of $36,928.31, a PE ratio of 22.94, a PEG ratio of 1.46 and a beta of 0.95. The company has a current ratio of 1.85, a quick ratio of 1.85 and a debt-to-equity ratio of 0.48.
Humana announced that its board has authorized a share buyback program on Thursday, December 14th that allows the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization allows the insurance provider to buy shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Investors of record on Friday, March 30th will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date is Wednesday, March 28th. This is a positive change from Humana’s previous quarterly dividend of $0.40. Humana’s dividend payout ratio is currently 9.59%.
In related news, SVP Cynthia H. Zipperle sold 1,196 shares of the company’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $273.33, for a total value of $326,902.68. Following the sale, the senior vice president now owns 7,771 shares in the company, valued at approximately $2,124,047.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider M Todoroff Christopher sold 16,389 shares of the company’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $273.37, for a total transaction of $4,480,260.93. Following the completion of the sale, the insider now owns 13,447 shares in the company, valued at approximately $3,676,006.39. The disclosure for this sale can be found here. Insiders sold a total of 41,775 shares of company stock worth $11,169,845 in the last 90 days. 0.60% of the stock is currently owned by company insiders.
HUM has been the topic of a number of research analyst reports. Leerink Swann upped their price target on shares of Humana from $280.00 to $300.00 and gave the company an “outperform” rating in a research report on Thursday, February 8th. Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $297.00 price target on the stock in a research report on Monday, January 15th. ValuEngine cut shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $250.00 price target on shares of Humana in a research report on Wednesday, February 7th. Finally, Oppenheimer upped their price target on shares of Humana from $275.00 to $305.00 and gave the company an “outperform” rating in a research report on Thursday, February 8th. Eight research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $270.47.
ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/03/14/earnest-partners-llc-has-31-37-million-position-in-humana-inc-hum.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.